Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne HodgkinsonCelia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Gabor Rum, Cavit Boz, Eva Havrdova, Helmut Butzkueven

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)425-435
JournalAnnals of Neurology
Volume77
Issue number3
DOIs
Publication statusPublished - Mar 2015

Cite this

Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., Duquette, P., Girard, M., Pucci, E., Lechner-Scott, J., Slee, M., Fernandez-Bolanos, R., Grand'Maison, F., Hupperts, R., Verheul, F., ... Butzkueven, H. (2015). Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis. Annals of Neurology, 77(3), 425-435. https://doi.org/10.1002/ana.24339